UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effects of Resmetirom on Noninvasive Endpoints in a 36‐Week Phase 2 Active Treatment Extension Study in Patients With NASH

Hepatology communications, 2021-04, Vol.5 (4), p.573-588

2021

Volltextzugriff (PDF)

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

The Lancet (British edition), 2018-11, Vol.392 (10160), p.2180-2193

2018

Volltextzugriff (PDF)

Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens

Diabetes, obesity & metabolism, 2020-06, Vol.22 (6), p.938-946

2020

Volltextzugriff (PDF)

An update on tirzepatide for the management of type 2 diabetes: a focus on the phase 3 clinical development program

Expert review of endocrinology & metabolism, 2023-03, Vol.18 (2), p.111-130

Frías, Juan Pablo

2023

Volltextzugriff (PDF)

Pegbelfermin (BMS‐986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study

Obesity (Silver Spring, Md.), 2019-01, Vol.27 (1), p.41-49

2019

Volltextzugriff (PDF)

Tirzepatide in Hispanic/Latino Patients With Type 2 Diabetes: A Subgroup Analysis of the SURPASS Program

The journal of clinical endocrinology and metabolism, 2024-01, Vol.109 (2), p.557-568

2024

Volltextzugriff (PDF)

Efficacy and safety of once‐weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE‐D, AMPLITUDE‐L and AMPLITUDE‐S randomized controlled trials

Diabetes, obesity & metabolism, 2023-08, Vol.25 (8), p.2084-2095

2023

Volltextzugriff (PDF)

The SYDNEY Device Study: A Multicenter, Randomized, Open-label Usability Study of a 2-mL Alirocumab Autoinjector Device

Clinical therapeutics, 2020-01, Vol.42 (1), p.94-107.e5

2020

Volltextzugriff (PDF)

Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes

Journal of diabetes and its complications, 2019-03, Vol.33 (3), p.236-242

2019

Volltextzugriff (PDF)

Impact of disease duration and β‐cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon‐like peptide‐1 receptor agonist therapy: Exploratory analyses from the LixiLan‐G trial

Diabetes, obesity & metabolism, 2020-09, Vol.22 (9), p.1567-1576

2020

Volltextzugriff (PDF)

Impact of lixisenatide dose range on clinical outcomes with fixed-ratio combination iGlarLixi in patients with type 2 diabetes

Current medical research and opinion, 2019-04, Vol.35 (4), p.689-695

2019

Volltextzugriff (PDF)

CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes

Cardiovascular diabetology, 2024-03, Vol.23 (1), p.104-104, Article 104

2024

Volltextzugriff (PDF)

Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis

The New England journal of medicine, 2024-07, Vol.391 (4), p.299-310

2024

Volltextzugriff (PDF)

Prioritising injectable therapies in the management of type 2 diabetes

The lancet. Diabetes & endocrinology, 2019-07, Vol.7 (7), p.505-508

Frias, Juan Pablo

2019

Volltextzugriff (PDF)

Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetes

Expert review of endocrinology & metabolism, 2019-03, Vol.14 (2), p.75-83

Frias, Juan Pablo

2019

Volltextzugriff (PDF)

The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes

Cell metabolism, 2017-08, Vol.26 (2), p.343-352.e2

2017

Volltextzugriff (PDF)

Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial

Diabetes care, 2022-07, Vol.45 (7), p.1592-1600

2022

Volltextzugriff (PDF)

Obesity among Latinx people in the United States: A review

Obesity (Silver Spring, Md.), 2023-02, Vol.31 (2), p.329-337

2023

Volltextzugriff (PDF)

Safety of Once-weekly Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes

The Journal of family practice, 2018-06, Vol.67 (6 suppl), p.S25-S34

Frias, Juan P

2018

Volltextzugriff (PDF)

Fixed-ratio Combinations (basal Insulin Plus GLP-1RA) In Type 2 Diabetes. an Analytical Review Of Pivotal Clinical Trials

The review of diabetic studies, 2023-03, Vol.19 (1), p.14-27

2023

Volltextzugriff (PDF)

New Basal Insulins: a Clinical Perspective of Their Use in the Treatment of Type 2 Diabetes and Novel Treatment Options Beyond Basal Insulin

Current diabetes reports, 2017-10, Vol.17 (10), p.91-91, Article 91

2017

Volltextzugriff (PDF)

78-LB: Efficacy and Safety of Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Compared with Insulin Degludec in Patients with Type 2 Diabetes (SURPASS-3)

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Volltextzugriff (PDF)

You have access78-LB: Efficacy and Safety of Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Compared with Insulin Degludec in Patients with Type 2 Diabetes (SURPASS-3)

Diabetes (New York, N.Y.), 2021-06, Vol.70

2021

Volltextzugriff (PDF)

BIO89-100 Demonstrated Robust Reductions in Liver Fat, Improved Metabolic Parameters, Favorable Tolerability and Potential for Weekly (QW) or Every 2 Weeks (Q2W) Dosing in a Phase 1b/2a Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in NASH

Metabolism, clinical and experimental, 2022-03, Vol.128, p.155016, Article 155016

2022

Volltextzugriff (PDF)

836-P: A Prebiotic Fiber Blend Improved Postprandial Glucose (PPG) and Time in Range (TIR) as Evaluated by Continuous Glucose Monitoring (CGM) in Healthy Subjects with Normal Glucose Tolerance

Diabetes (New York, N.Y.), 2022-06, Vol.71 (Supplement_1)

2022

Volltextzugriff (PDF)

1 – 25 von 73

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(59)
Mit Volltextzugriff
(66)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(37)
Life Sciences & Biomedicine
(35)
Humans
(22)
Diabetes
(19)
Endocrinology & Metabolism
(17)
Diabetes Mellitus, Type 2 - Drug Therapy
(14)
Diabetes Mellitus
(13)
Type 2 Diabetes
(12)
Glucose
(11)
Hypoglycemia
(10)
Adult
(9)
Body Weight
(9)
Female
(9)
Insulin
(9)
Middle Aged
(9)
Clinical Trials
(8)
Glucagon
(8)
Male
(8)
Metabolism
(8)
Patients
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Effects of Resmetirom on Noninvasive Endpoints in a 36‐Week Phase 2 Active Treatment Extension Study in Patients With NASH

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens

An update on tirzepatide for the management of type 2 diabetes: a focus on the phase 3 clinical development program

Pegbelfermin (BMS‐986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study

Tirzepatide in Hispanic/Latino Patients With Type 2 Diabetes: A Subgroup Analysis of the SURPASS Program

Efficacy and safety of once‐weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE‐D, AMPLITUDE‐L and AMPLITUDE‐S randomized controlled trials

The SYDNEY Device Study: A Multicenter, Randomized, Open-label Usability Study of a 2-mL Alirocumab Autoinjector Device

Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes

Impact of disease duration and β‐cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon‐like peptide‐1 receptor agonist therapy: Exploratory analyses from the LixiLan‐G trial

Impact of lixisenatide dose range on clinical outcomes with fixed-ratio combination iGlarLixi in patients with type 2 diabetes

CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes

Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis

Prioritising injectable therapies in the management of type 2 diabetes

Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetes

The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes

Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial

Obesity among Latinx people in the United States: A review

Safety of Once-weekly Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes

Fixed-ratio Combinations (basal Insulin Plus GLP-1RA) In Type 2 Diabetes. an Analytical Review Of Pivotal Clinical Trials

New Basal Insulins: a Clinical Perspective of Their Use in the Treatment of Type 2 Diabetes and Novel Treatment Options Beyond Basal Insulin

78-LB: Efficacy and Safety of Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Compared with Insulin Degludec in Patients with Type 2 Diabetes (SURPASS-3)

You have access78-LB: Efficacy and Safety of Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Compared with Insulin Degludec in Patients with Type 2 Diabetes (SURPASS-3)

BIO89-100 Demonstrated Robust Reductions in Liver Fat, Improved Metabolic Parameters, Favorable Tolerability and Potential for Weekly (QW) or Every 2 Weeks (Q2W) Dosing in a Phase 1b/2a Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in NASH

836-P: A Prebiotic Fiber Blend Improved Postprandial Glucose (PPG) and Time in Range (TIR) as Evaluated by Continuous Glucose Monitoring (CGM) in Healthy Subjects with Normal Glucose Tolerance

Suchergebnisse filtern